Piroxicam cocrystals with phenolic coformers: preparation, characterization, and dissolution properties

References

• Aitipamula S, Banerjee R, Bansal AK, Biradha K, Cheney ML, Choudhury AR, Desiraju GR, Dikundwar AG, Dubey R, Duggirala N. 2012. Polymorphs, salts, and cocrystals: what’s in a name? Cryst Growth Des. 12:2147–2152.
   Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 12:413–420.
   PubMed Web of Science ®Google Scholar
• Arenas-García JI, Herrera-Ruiz D, Morales-Rojas H, Höpfl H. 2017. Interrelation of the dissolution behavior and solid-state features of acetazolamide cocrystals. Eur J Pharm Sci. 96:299–308.
   PubMed Web of Science ®Google Scholar
• Babu NJ, Nangia A. 2011. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des. 11:2662–2679.
   Web of Science ®Google Scholar
• Banerjee R, Bhatt PM, Ravindra NV, Desiraju GR. 2005. Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities. Cryst Growth Des. 5:2299–2309.
   Web of Science ®Google Scholar
• Barzegar-Jalali M, Maleki N, Garjani A, Khandar A, Haji-Hosseinloo M, Jabbari R, Dastmalchi S. 2002. Enhancement of dissolution rate and anti-inflammatory effects of piroxicam using solvent deposition technique. Drug Dev Ind Pharm. 28:681–686.
   PubMed Web of Science ®Google Scholar
• Betigeri S, Thakur A, Shukla R, Raghavan K. 2008. Effect of polymer additives on the transformation of BMS-566394 anhydrate to the dihydrate form. Pharm Res. 25:1043–1051.
   PubMed Web of Science ®Google Scholar
• Bolla G, Sanphui P, Nangia A. 2013. Solubility advantage of tenoxicam phenolic cocrystals compared to salts. Cryst Growth Des. 13:1988–2003.
   Web of Science ®Google Scholar
• Childs SL, Chyall LJ, Dunlap JT, Smolenskaya VN, Stahly BC, Stahly GP. 2004. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc. 126:13335–13342.
   PubMed Web of Science ®Google Scholar
• Childs SL, Hardcastle KI. 2007. Cocrystals of piroxicam with carboxylic acids. Cryst Growth Des. 7:1291–1304.
   Web of Science ®Google Scholar
• Gomes DJ, de Souza NC, Silva JR. 2013. Using a monocular optical microscope to assemble a wetting contact angle analyser. Measurement. 46:3623–3627.
   Web of Science ®Google Scholar
• Good DJ, Rodri´guez-Hornedo N. 2009. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des. 9:2252–2264.
   Web of Science ®Google Scholar
• Greco K, Bogner R. 2012. Solution-mediated phase transformation: significance during dissolution and implications for bioavailability. J Pharm Sci. 101:2996–3018.
   PubMed Web of Science ®Google Scholar
• Gwak H-S, Choi J-S, Choi H-K. 2005. Enhanced bioavailability of piroxicam via salt formation with ethanolamines. Int J Pharm. 297:156–161.
   PubMed Web of Science ®Google Scholar
• Karki S, Friščić T, Fábián L, Laity PR, Day GM, Jones W. 2009. Improving mechanical properties of crystalline solids by cocrystal formation: new compressible forms of paracetamol. Adv Mater. 21:3905–3909.
   Web of Science ®Google Scholar
• Khan T, Ranjan R, Dogra Y, Pandya SM, Shafi H, Singh S, Yadav PN, Misra A. 2016. Intranasal eutectic powder of zolmitriptan with enhanced bioavailability in the rat brain. Mol Pharm. 13:3234–3240.
   PubMedGoogle Scholar
• Kirchmeyer W, Wyttenbach N, Alsenz J, Kuentz M. 2015. Influence of excipients on solvent-mediated hydrate formation of piroxicam studied by dynamic imaging and fractal analysis. Cryst Growth Des. 15:5002–5010.
   Web of Science ®Google Scholar
• Kogermann K, Penkina A, Predbannikova K, Jeeger K, Veski P, Rantanen J, Naelapää K. 2013. Dissolution testing of amorphous solid dispersions. Int J Pharm. 444:40–46.
   PubMed Web of Science ®Google Scholar
• Kumar SS, Nangia A. 2014. A solubility comparison of neutral and zwitterionic polymorphs. Cryst Growth Des. 14:1865–1881.
   Web of Science ®Google Scholar
• Lazghab M, Saleh K, Pezron I, Guigon P, Komunjer L. 2005. Wettability assessment of finely divided solids. Powder Technol. 157:79–91.
   Web of Science ®Google Scholar
• Liu X, Lu M, Guo Z, Huang L, Feng X, Wu C. 2012. Improving the chemical stability of amorphous solid dispersion with cocrystal technique by hot melt extrusion. Pharm Res. 29:806–817.
   PubMed Web of Science ®Google Scholar
• Lu E, Rodríguez-Hornedo N, Suryanarayanan R. 2008. A rapid thermal method for cocrystal screening. CrystEngComm. 10:665–668.
   Web of Science ®Google Scholar
• Lu Y, Tang N, Lian R, Qi J, Wu W. 2014. Understanding the relationship between wettability and dissolution of solid dispersion. Int J Pharm. 465:25–31.
   PubMed Web of Science ®Google Scholar
• Lust A, Laidmäe I, Palo M, Meos A, Aaltonen J, Veski P, Heinämäki J, Kogermann K. 2013. Solid-state dependent dissolution and oral bioavailability of piroxicam in rats. Eur J Pharm Sci. 48:47–54.
   PubMed Web of Science ®Google Scholar
• Manin AN, Voronin AP, Drozd KV, Manin NG, Bauer-Brandl A, Perlovich GL. 2014. Cocrystal screening of hydroxybenzamides with benzoic acid derivatives: a comparative study of thermal and solution-based methods. Eur J Pharm Sci. 65:56–64.
   PubMed Web of Science ®Google Scholar
• Mosharraf M, Nyström C. 2003. Apparent solubility of drugs in partially crystalline systems. Drug Dev Ind Pharm. 29:603–622.
   PubMed Web of Science ®Google Scholar
• Paaver U, Lust A, Mirza S, Rantanen J, Veski P, Heinämäki J, Kogermann K. 2012. Insight into the solubility and dissolution behavior of piroxicam anhydrate and monohydrate forms. Int J Pharm. 431:111–119.
   PubMed Web of Science ®Google Scholar
• Patel JR, Carlton RA, Needham TE, Chichester CO, Vogt FG. 2012. Preparation, structural analysis, and properties of tenoxicam cocrystals. Int J Pharm. 436:685–706.
   PubMedGoogle Scholar
• Rahman Z, Agarabi C, Zidan AS, Khan SR, Khan MA. 2011. Physico-mechanical and stability evaluation of carbamazepine cocrystal with nicotinamide. AAPS PharmSciTech. 12:693–704.
   PubMed Web of Science ®Google Scholar
• Remenar JF, Peterson ML, Stephens PW, Zhang Z, Zimenkov Y, Hickey MB. 2007. Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential. Mol Pharm. 4:386–400.
   PubMedGoogle Scholar
• Sauceau M, Rodier E, Fages J. 2008. Preparation of inclusion complex of piroxicam with cyclodextrin by using supercritical carbon dioxide. J Supercrit Fluids. 47:326–332.
   Web of Science ®Google Scholar
• Schultheiss N, Newman A. 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 9:2950–2967.
   PubMed Web of Science ®Google Scholar
• Shayanfar A, Asadpour-Zeynali K, Jouyban A. 2013. Solubility and dissolution rate of a carbamazepine–cinnamic acid cocrystal. J Mol Liq. 187:171–176.
   Web of Science ®Google Scholar
• Sheth AR, Zhou D, Muller FX, Grant DJ. 2004. Dehydration kinetics of piroxicam monohydrate and relationship to lattice energy and structure. J Pharm Sci. 93:3013–3026.
   PubMed Web of Science ®Google Scholar
• Shiraki K, Takata N, Takano R, Hayashi Y, Terada K. 2008. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm Res. 25:2581–2592.
   PubMed Web of Science ®Google Scholar
• Sowa M, Ślepokura K, Matczak-Jon E. 2014. Improving solubility of fisetin by cocrystallization. CrystEngComm. 16:10592–10601.
   Web of Science ®Google Scholar
• Stepanovs D, Jure M, Kuleshova LN, Hofmann DW, Mishnev A. 2015. Cocrystals of pentoxifylline: in silico and experimental screening. Cryst Growth Des. 15:3652–3660.
   Web of Science ®Google Scholar
• Swanepoel E, Liebenberg W, De Villiers MM, Dekker TG. 2000. Dissolution properties of piroxicam powders and capsules as a function of particle size and the agglomeration of powders. Drug Dev Ind Pharm. 26:1067–1076.
   PubMed Web of Science ®Google Scholar
• Taddei P, Torreggiani A, Simoni R. 2001. Influence of environment on piroxicam polymorphism: vibrational spectroscopic study. Biopolymers. 62:68–78.
   PubMed Web of Science ®Google Scholar
• Valizadeh H, Zakeri-Milani P, Barzegar-Jalali M, Mohammadi G, Danesh-Bahreini M-A, Adibkia K, Nokhodchi A. 2007. Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers. Drug Dev Ind Pharm. 33:45–56.
   PubMed Web of Science ®Google Scholar
• Vrečer F, Vrbinc M, Meden A. 2003. Characterization of piroxicam crystal modifications. Int J Pharm. 256:3–15.
   PubMed Web of Science ®Google Scholar
• Wales C, Thomas LH, Wilson CC. 2012. Tautomerisation and polymorphism in molecular complexes of piroxicam with mono-substituted benzoic acids. CrystEngComm. 14:7264–7274.
   Web of Science ®Google Scholar
• Wang Z-Z, Chen J-M, Lu T-B. 2012. Enhancing the hygroscopic stability of S-oxiracetam via pharmaceutical cocrystals. Cryst Growth Des. 12:4562–4566.
   Web of Science ®Google Scholar
• Weyna DR, Cheney ML, Shan N, Hanna M, Zaworotko MJ, Sava V, Song S, Sanchez-Ramos JR. 2012. Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation. Mol Pharm. 9:2094–2102.
   PubMedGoogle Scholar
• Yalkowsky SH, He Y, Jain P. 2016. Handbook of aqueous solubility data. Boca Raton (FL): CRC Press.
   Google Scholar
• Yamashita H, Hirakura Y, Yuda M, Terada K. 2014. Coformer screening using thermal analysis based on binary phase diagrams. Pharm Res. 31:1946–1957.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S. 2010. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 12:263–271.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Chan HM, Sung HH-Y, Tong HH, Zheng Y. 2016. Identification of new cocrystal systems with stoichiometric diversity of salicylic acid using thermal methods. Pharm Res. 33:1030–1039.
   PubMed Web of Science ®Google Scholar